Results 61 to 70 of about 12,211 (152)

Natalizumab [PDF]

Reactions Weekly, 2020
openaire   +2 more sources

Natalizumab for the treatment of relapsing multiple sclerosis

Biologics: Targets & Therapy, 2008
Richard A Rudick1, Michael A Panzara21Cleveland Clinic Foundation, Cleveland, OH, USA; 2Biogen Idec, Inc., Cambridge, MA, USAAbstract: Natalizumab is an α4-integrin antagonist approved as monotherapy for patients with relapsing multiple ...
Richard A Rudick, Michael A Panzara
doaj  

Changes in JC virus-specific T cell responses during natalizumab treatment and in natalizumab-associated progressive multifocal leukoencephalopathy.

PLoS Pathogens, 2012
Progressive multifocal leukoencephalopathy (PML) induced by JC virus (JCV) is a risk for natalizumab-treated multiple sclerosis (MS) patients. Here we characterize the JCV-specific T cell responses in healthy donors and natalizumab-treated MS patients to
Molly R Perkins, Caroline Ryschkewitsch, Julia C Liebner, Maria Chiara G Monaco, Danielle Himelfarb, Sara Ireland, Annelys Roque, Heather L Edward, Peter N Jensen, Gina Remington, Thomas Abraham, Jaspreet Abraham, Benjamin Greenberg, Charles Kaufman, Chris LaGanke, Nancy L Monson, Xiaoning Xu, Elliot Frohman, Eugene O Major, Daniel C Douek   +19 more
doaj   +1 more source

Bruising following natalizumab infusion for relapsing-remitting multiple sclerosis: a case report

Journal of Medical Case Reports, 2009
Introduction Natalizumab is a new treatment for relapsing-remitting multiple sclerosis. Because of limited experience of this treatment, medical professionals must be alert to possible side effects.
Gatzonis Stylianos, Siatouni Anna
doaj   +1 more source

Impact of Natalizumab on Productivity and Ability to Work in Patients with Multiple Sclerosis in France: The TITAN Study

Neurology and Therapy
Introduction The TITAN study examined changes in productivity, ability to work, and quality of life (QoL) before and after treatment with the high-efficacy therapy natalizumab (TYSABRI®) in patients with multiple sclerosis (MS) in France.
Patrick Vermersch, Arnaud Kwiatkowski, Jérôme de Sèze, Alain Créange, Nathalie Texier, Sophie Fantoni-Quinton, Marilyn Gros, Marta Ruiz, Christine Lebrun-Frenay, on behalf of the TITAN Investigators   +9 more
doaj   +1 more source

A comparison of natalizumab and ocrelizumab on disease progression in multiple sclerosis

Annals of Clinical and Translational Neurology
Objective No direct comparisons of the effect of natalizumab and ocrelizumab on progression independent of relapse activity (PIRA) and relapse‐associated worsening (RAW) events are currently available.
Pietro Iaffaldano, Giuseppe Lucisano, Tommaso Guerra, Damiano Paolicelli, Emilio Portaccio, Matilde Inglese, Matteo Foschi, Francesco Patti, Franco Granella, Silvia Romano, Paola Cavalla, Giovanna De Luca, Paolo Gallo, Paolo Bellantonio, Antonio Gallo, Sara Montepietra, Alessia Di Sapio, Marika Vianello, Rocco Quatrale, Daniele Spitaleri, Raffaella Clerici, Valentina Torri Clerici, Eleonora Cocco, Vincenzo Brescia Morra, Girolama Alessandra Marfia, Vincenzo Daniele Boccia, Massimo Filippi, Maria Pia Amato, Maria Trojano, the Italian MS Register   +29 more
doaj   +1 more source

Patient Preference for Subcutaneous Versus Intravenous Administration with Every-6-Week Natalizumab (Tysabri®) Dosing: NOVA Phase IIIb Extension Study (Part 2)

Neurology and Therapy
Introduction Following NOVA (part 1) and the approval of the subcutaneous (SC) route of administration of natalizumab by the European Medicines Agency, an extension phase of the NOVA phase IIIb study (part 2) was initiated to collect patient preference ...
Heinz Wiendl, John Foley, Gilles Defer, Lana Zhovtis Ryerson, Jeffrey A. Cohen, Douglas L. Arnold, Helmut Butzkueven, Gary R. Cutter, Gavin Giovannoni, Joep Killestein, Rose Domingo-Horne, Marie Toukam, Aimie Nunn, Amir-Hadi Maghzi, Robert Kuhelj, Tyler Lasky   +15 more
doaj   +1 more source

Reducing return of disease activity in patients with relapsing multiple sclerosis transitioned from natalizumab to teriflunomide: 12-month interim results of teriflunomide therapy

Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2019
Background Natalizumab is an effective treatment for relapsing multiple sclerosis. Return of disease activity upon natalizumab discontinuance creates the need for follow-up therapeutic strategies.
Stanley L Cohan, Keith Edwards, Lindsay Lucas, Tiffany Gervasi-Follmar, Judy O’Connor, Jessica Siuta, Vineetha Kamath, Lore Garten, Chiayi Chen, James Thomas, Kyle Smoot, Kiren Kresa-Reahl, Kateri J Spinelli   +12 more
doaj   +1 more source

In vitro morphological profiling of T cells predicts clinical response to natalizumab therapy in patients with multiple sclerosis

Nature Communications
Despite the efficacy of natalizumab, which targets the integrin VLA-4, in treating multiple sclerosis (MS), approximately 35% patients with MS present evidence of disease activity two years after treatment initiation.
Beatriz Chaves, Juan Carlo Santos e Silva, Helder Nakaya, Nicolas Socquet-Juglard, Florence Bucciarelli, Guilhèn Prunier, Matheus V. Almeida, Claire Lacouture, Saniya Kari, Anne L. Astier, Marco A. Medeiros, João H. M. Silva, Roland Liblau, Vinicius Cotta-de-Almeida, Loïc Dupré   +14 more
doaj   +1 more source

NEDA-3 status including cortical lesions in the comparative evaluation of natalizumab fingolimod efficacy in multiple sclerosis

Therapeutic Advances in Neurological Disorders, 2018
Background: Cortical lesions (CLs) are typical of multiple sclerosis (MS) and have been recently incorporated in MS diagnostic criteria. Thus, the ‘no evidence of disease activity’ (NEDA) definition should now include CLs.
Marco Puthenparampil, Chiara Cazzola, Sofia Zywicki, Lisa Federle, Erica Stropparo, Mariagiulia Anglani, Francesca Rinaldi, Paola Perini, Paolo Gallo   +8 more
doaj   +1 more source